Andrew X. Zhu, MD, PhD

Publications

Kalva SP, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S, Zhu AX.Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.Gastrointest Cancer Res. 2011 Jan;4(1):2-8.
21464864
Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX.A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.Oncologist. 2011;16(3):310-8.
21349948
Zhu AX, Duda DG, Sahani DV, Jain RK.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol. 2011 Mar 8.
21386818
Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.BMC Cancer. 2011;11:60.
21303542
Zhu AX, Hezel AF.Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Hepatology. 2011 Feb;53(2):695-704. Review.
21274890
Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and ga
21217058
Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.Cancer Chemother P
20960192
Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.Clin Cancer Res. 2010 Sep
20843836
Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8.
20130879
Poultsides GA, Zhu AX, Choti MA, Pawlik TM.Intrahepatic cholangiocarcinoma.Surg Clin North Am. 2010 Aug;90(4):817-37. Review.
20637950
Hezel AF, Deshpande V, Zhu AX.Genetics of biliary tract cancers and emerging targeted therapies.J Clin Oncol. 2010 Jul 20;28(21):3531-40. Review.
20547994
Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX.Phase II study of darinaparsin in patients with advanced hepatocellular ca
19565187
Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P.A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
20472683
Burak KW, Thomas MB, Zhu AX.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.Hpb : The Official Journal Of The International Hepato Pancreato Biliary Association. 2010 Jun;12(5):321-2.
20590906
Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, Mentha G, Terris B.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and
20459550
Zhu AX.Systemic treatment of hepatocellular carcinoma: dawn of a new era?.Ann Surg Oncol. 2010 May;17(5):1247-56. Review.
20405329
Zhu AX.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Expert Opin Investig Drugs. 2010 May;19(5):663-72. Review.
20367287
Zhu AX, Hong TS, Hezel AF, Kooby DA.Current management of gallbladder carcinoma.Oncologist. 2010;15(2):168-81. Review.
20147507
Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.Efficacy and safety of gemcitabine
19932054
Lipworth AD, Robert C, Zhu AX.Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.Oncology. 2009;77(5):257-71. Review.
19923864
Zhu AX, El-Khoueiry A, Llovet JM.Accomplishments in 2008 in the management of hepatobiliary cancers.Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S28-36.
20011562
Siegel AB, Zhu AX.Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.Cancer. 2009 Dec 15;115(24):5651-61. Review.
19834957
Cleary JM, Tanabe KT, Lauwers GY, Zhu AX.Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.Oncologist. 2009 Nov;14(11):1095-105. Review.
19880627
Zhu AX.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?.BMC Med. 2009;7:42.
19703270
Zhu AX, Duda DG, Sahani DV, Jain RK.Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.Cancer J.;15(4):263-8. Review.
19672141
Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX.Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.Oncologist. 2009 Jul;14(7):717-25.
19581525
Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Bioma
19470923
Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG.Biomarkers of response and resistance to antiangiogenic therapy.Nat Rev Clin Oncol. 2009 Jun;6(6):327-338. Review.
19483739
Benson AB 3rd,Abrams TA,Ben-Josef E,Bloomston PM,Botha JF,Clary BM,Covey A,Curley SA,D'Angelica MI,Davila R,Ensminger WD,Gibbs JF,Laheru D,Malafa MP,Marrero J,Meranze SG,Mulvihill SJ,Park JO,Posey JA,Sachdev J,Salem R,Sigurdson ER,Sofocleous C,Vauthey
19406039
Finn RS,Zhu AX.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. Review.
19374603
Goulart BH,Clark JW,Lauwers GY,Ryan DP,Grenon N,Muzikansky A,Zhu AX.Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.J Hematol Oncol. 2009;2:13.
19291303
Zhu AX,Clark JW.Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.Oncologist. 2009 Jan;14(1):67-9.
19147690
Zhu AX,Ready N,Clark JW,Safran H,Amato A,Salem N,Pace S,He X,Zvereva N,Lynch TJ,Ryan DP,Supko JG.Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.Clin Cancer Res. 2009 Jan 1;15
19118068
Zhu AX,Raymond E.Early development of sunitinib in hepatocellular carcinoma.Expert Rev Anticancer Ther. 2009 Jan;9(1):143-50. Review.
19105714
Nathan H,Aloia TA,Vauthey JN,Abdalla EK,Zhu AX,Schulick RD,Choti MA,Pawlik TM.A proposed staging system for intrahepatic cholangiocarcinoma.Ann Surg Oncol. 2009 Jan;16(1):14-22.
18987916
Sainani NI,Catalano OA,Holalkere NS,Zhu AX,Hahn PF,Sahani DV.Cholangiocarcinoma: current and novel imaging techniques.Radiographics. 2008 Sep-Oct;28(5):1263-87. Review.
18794305
Asomaning K,Reid AE,Zhou W,Heist RS,Zhai R,Su L,Kwak EL,Blaszkowsky L,Zhu AX,Ryan DP,Christiani DC,Liu G.MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.Clin Cancer Res. 2008 Jun 15;14(12):4010-5.
18559624
Llovet JM,Di Bisceglie AM,Bruix J,Kramer BS,Lencioni R,Zhu AX,Sherman M,Schwartz M,Lotze M,Talwalkar J,Gores GJ.Design and endpoints of clinical trials in hepatocellular carcinoma.Journal of the National Cancer Institute. 2008 May 21;100(10):698-711. Revi
18477802
Hezel AF, Zhu AX.Systemic therapy for biliary tract cancers.Oncologist. 2008 Apr;13(4):415-23. Review.
18448556
Zhu AX.Successful targeted therapies for hepatocellular carcinoma: are we really getting there?.Expert Rev Anticancer Ther. 2008 Apr;8(4):499-505.
18402516
Zhu AX, Abou-Alfa GK.Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.JAMA. 2008 Apr 9;299(14):1716-8.
18398085
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.Cancer Res. 2008 Apr 1;68(7):
18381447
Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV.Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.Oncologist. 2008 Feb;13(2):120-5.
18305056
Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS.Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer.Dig Dis Sci. 2008 Feb;53(2):564-70.
17597402
Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G.Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma.Cancer. 2008 Mar 1;112(5
18205184
Zhu AX.Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.Cancer. 2008 Jan 15;112(2):250-9.
18041064
Ng K, Zhu AX.Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20. Review.
18006328
Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92.
17947726
Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS.Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients
17216531
Meyerhardt J, Stuart K, Fuchs C, Zhu A, Earle C, Bhargava P, Blaszkowsky L, Enzinger P, Mayer R, Battu S, Lawrence C, Ryan D.Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.Ann Onco
17483115
Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.Cancer. 2007 Aug 1;110(3):581-9.
17583545
Sahani DV, Holalkere NS, Mueller PR, Zhu AX.Advanced Hepatocellular Carcinoma: CT Perfusion of Liver and Tumor Tissue--Initial Experience.Radiology. 2007 Jun;243(3):736-43.
17517931
Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.Cancer Chemother Pharmacol. 2007 Jul;60(2):203-9.
17091249
Zhou X, Chen B, Hoopes PJ, Hasan T, Pogue BW.Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the dunning rat prostate tumor.Photochem Photobiol. 2006 Sep-Oct;82(5):1348-57.
17421078
Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y, Fuchs BC, Kawasaki H, Tanabe KK.Positron emission tomography of herpes simplex virus 1 oncolysis.Cancer Res. 2007 Apr 1;67(7):3295-300.
17409438
Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL.Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind
17394940
Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastroin
16786333
Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(1
17036355
Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS.Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.Clin Colorectal Cancer. 2006 Sep;6(3):2
17026790
Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Cl
16877721
Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 Jun;51(6):1033-8.
16865563
Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS.Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.C
16796793
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.J Cli
16622265
Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.J Clin On
16622264
Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients
16362299
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY.Surrogate mark
16258121
Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.Oncologist. 2005 Jun-Jul;10(6):392-8.
15967833
Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL.Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.Pancreatology. 2005;5(1):67
15775701
Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL.Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.Ann Surg. 2005 Feb;241(2):29
15650640
Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, Terella A, Hertl M, Cosimi AB, Chung RT.Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.Liver Transpl. 2004 Nov;10(11):1343-54.
15497158

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Andrew X. Zhu, MD, PhD Publications Kalva SP, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S, Zhu AX.Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.Gastrointest Cancer Res. 2011 Jan;4(1):2-8. 21464864 Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX.A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.Oncologist. 2011;16(3):310-8. 21349948 Zhu AX, Duda DG, Sahani DV, Jain RK.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol. 2011 Mar 8. 21386818 Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.BMC Cancer. 2011;11:60. 21303542 Zhu AX, Hezel AF.Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Hepatology. 2011 Feb;53(2):695-704. Review. 21274890 Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS.A multicenter phase II trial of single-agent cetuximab in advanced esophageal and ga 21217058 Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.Cancer Chemother P 20960192 Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.Clin Cancer Res. 2010 Sep 20843836 Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8. 20130879 Poultsides GA, Zhu AX, Choti MA, Pawlik TM.Intrahepatic cholangiocarcinoma.Surg Clin North Am. 2010 Aug;90(4):817-37. Review. 20637950 Hezel AF, Deshpande V, Zhu AX.Genetics of biliary tract cancers and emerging targeted therapies.J Clin Oncol. 2010 Jul 20;28(21):3531-40. Review. 20547994 Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX.Phase II study of darinaparsin in patients with advanced hepatocellular ca 19565187 Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P.A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics 20472683 Burak KW, Thomas MB, Zhu AX.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.Hpb : The Official Journal Of The International Hepato Pancreato Biliary Association. 2010 Jun;12(5):321-2. 20590906 Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, Mentha G, Terris B.Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and 20459550 Zhu AX.Systemic treatment of hepatocellular carcinoma: dawn of a new era?.Ann Surg Oncol. 2010 May;17(5):1247-56. Review. 20405329 Zhu AX.Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.Expert Opin Investig Drugs. 2010 May;19(5):663-72. Review. 20367287 Zhu AX, Hong TS, Hezel AF, Kooby DA.Current management of gallbladder carcinoma.Oncologist. 2010;15(2):168-81. Review. 20147507 Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.Efficacy and safety of gemcitabine 19932054 Lipworth AD, Robert C, Zhu AX.Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.Oncology. 2009;77(5):257-71. Review. 19923864 Zhu AX, El-Khoueiry A, Llovet JM.Accomplishments in 2008 in the management of hepatobiliary cancers.Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S28-36. 20011562 Siegel AB, Zhu AX.Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.Cancer. 2009 Dec 15;115(24):5651-61. Review. 19834957 Cleary JM, Tanabe KT, Lauwers GY, Zhu AX.Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.Oncologist. 2009 Nov;14(11):1095-105. Review. 19880627 Zhu AX.Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?.BMC Med. 2009;7:42. 19703270 Zhu AX, Duda DG, Sahani DV, Jain RK.Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.Cancer J.;15(4):263-8. Review. 19672141 Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX.Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.Oncologist. 2009 Jul;14(7):717-25. 19581525 Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Bioma 19470923 Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG.Biomarkers of response and resistance to antiangiogenic therapy.Nat Rev Clin Oncol. 2009 Jun;6(6):327-338. Review. 19483739 Benson AB 3rd,Abrams TA,Ben-Josef E,Bloomston PM,Botha JF,Clary BM,Covey A,Curley SA,D'Angelica MI,Davila R,Ensminger WD,Gibbs JF,Laheru D,Malafa MP,Marrero J,Meranze SG,Mulvihill SJ,Park JO,Posey JA,Sachdev J,Salem R,Sigurdson ER,Sofocleous C,Vauthey 19406039 Finn RS,Zhu AX.Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. Review. 19374603 Goulart BH,Clark JW,Lauwers GY,Ryan DP,Grenon N,Muzikansky A,Zhu AX.Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.J Hematol Oncol. 2009;2:13. 19291303 Zhu AX,Clark JW.Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.Oncologist. 2009 Jan;14(1):67-9. 19147690 Zhu AX,Ready N,Clark JW,Safran H,Amato A,Salem N,Pace S,He X,Zvereva N,Lynch TJ,Ryan DP,Supko JG.Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.Clin Cancer Res. 2009 Jan 1;15 19118068 Zhu AX,Raymond E.Early development of sunitinib in hepatocellular carcinoma.Expert Rev Anticancer Ther. 2009 Jan;9(1):143-50. Review. 19105714 Nathan H,Aloia TA,Vauthey JN,Abdalla EK,Zhu AX,Schulick RD,Choti MA,Pawlik TM.A proposed staging system for intrahepatic cholangiocarcinoma.Ann Surg Oncol. 2009 Jan;16(1):14-22. 18987916 Sainani NI,Catalano OA,Holalkere NS,Zhu AX,Hahn PF,Sahani DV.Cholangiocarcinoma: current and novel imaging techniques.Radiographics. 2008 Sep-Oct;28(5):1263-87. Review. 18794305 Asomaning K,Reid AE,Zhou W,Heist RS,Zhai R,Su L,Kwak EL,Blaszkowsky L,Zhu AX,Ryan DP,Christiani DC,Liu G.MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.Clin Cancer Res. 2008 Jun 15;14(12):4010-5. 18559624 Llovet JM,Di Bisceglie AM,Bruix J,Kramer BS,Lencioni R,Zhu AX,Sherman M,Schwartz M,Lotze M,Talwalkar J,Gores GJ.Design and endpoints of clinical trials in hepatocellular carcinoma.Journal of the National Cancer Institute. 2008 May 21;100(10):698-711. Revi 18477802 Hezel AF, Zhu AX.Systemic therapy for biliary tract cancers.Oncologist. 2008 Apr;13(4):415-23. Review. 18448556 Zhu AX.Successful targeted therapies for hepatocellular carcinoma: are we really getting there?.Expert Rev Anticancer Ther. 2008 Apr;8(4):499-505. 18402516 Zhu AX, Abou-Alfa GK.Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.JAMA. 2008 Apr 9;299(14):1716-8. 18398085 Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.Cancer Res. 2008 Apr 1;68(7): 18381447 Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV.Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.Oncologist. 2008 Feb;13(2):120-5. 18305056 Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS.Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer.Dig Dis Sci. 2008 Feb;53(2):564-70. 17597402 Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G.Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma.Cancer. 2008 Mar 1;112(5 18205184 Zhu AX.Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.Cancer. 2008 Jan 15;112(2):250-9. 18041064 Ng K, Zhu AX.Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20. Review. 18006328 Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92. 17947726 Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS.Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients 17216531 Meyerhardt J, Stuart K, Fuchs C, Zhu A, Earle C, Bhargava P, Blaszkowsky L, Enzinger P, Mayer R, Battu S, Lawrence C, Ryan D.Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.Ann Onco 17483115 Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.Cancer. 2007 Aug 1;110(3):581-9. 17583545 Sahani DV, Holalkere NS, Mueller PR, Zhu AX.Advanced Hepatocellular Carcinoma: CT Perfusion of Liver and Tumor Tissue--Initial Experience.Radiology. 2007 Jun;243(3):736-43. 17517931 Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.Cancer Chemother Pharmacol. 2007 Jul;60(2):203-9. 17091249 Zhou X, Chen B, Hoopes PJ, Hasan T, Pogue BW.Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the dunning rat prostate tumor.Photochem Photobiol. 2006 Sep-Oct;82(5):1348-57. 17421078 Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y, Fuchs BC, Kawasaki H, Tanabe KK.Positron emission tomography of herpes simplex virus 1 oncolysis.Cancer Res. 2007 Apr 1;67(7):3295-300. 17409438 Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL.Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind 17394940 Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastroin 16786333 Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(1 17036355 Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS.Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.Clin Colorectal Cancer. 2006 Sep;6(3):2 17026790 Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Cl 16877721 Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 Jun;51(6):1033-8. 16865563 Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS.Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.C 16796793 Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.J Cli 16622265 Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.J Clin On 16622264 Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients 16362299 Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY.Surrogate mark 16258121 Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.Oncologist. 2005 Jun-Jul;10(6):392-8. 15967833 Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL.Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.Pancreatology. 2005;5(1):67 15775701 Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL.Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.Ann Surg. 2005 Feb;241(2):29 15650640 Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, Terella A, Hertl M, Cosimi AB, Chung RT.Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.Liver Transpl. 2004 Nov;10(11):1343-54. 15497158
Site Map Site Feedback Web Privacy Policy